Signed in as:
filler@godaddy.com
Signed in as:
filler@godaddy.com
History & Background:
Cannabielsoin (CBE) was first identified in 1970 by a team of researchers in Israel. While it has been studied less extensively than other cannabinoids, initial research suggests that CBE may have a range of therapeutic effects.
CBE is formed from CBD during the metabolic process. This means it is a metabolite of CBD.
Benefits of CBE:
While research on CBE is limited, early studies suggest that it may have a range of potential benefits. For example, some research has suggested that CBE may have anti-inflammatory properties, making it a possible treatment for conditions such as arthritis or Crohn's disease. Additionally, CBE may have analgesic effects, meaning it could be useful for managing pain. Some studies have also suggested that CBE may have neuroprotective properties and could be useful in treating conditions such as Alzheimer's disease or Parkinson's disease.
Cultivars That Exhibit Higher-Than-Average Levels Of CBE:
(current belief is that High-CBD Hemp cultivars will be highest in CBE)
(CULTIVARS TBA)
Risks of CBE Use:
As with any substance, there are some risks associated with using CBE. While there have been no reported cases of overdose or death due to CBE, it may interact with other medications, so it is important to talk to a healthcare provider before using it. Additionally, while CBE has been shown to have therapeutic potential, more research is needed to fully understand its effects and potential side effects.